Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Khashayar Esfahani

Showing results (1-10 of 47) with videos related to

Pageof 5
Sort By:
Journal for Immunotherapy of Cancer|December 23, 2018
Taking the bull by the horn: the frontline use of infliximab for the treatment of immune checkpoint inhibitor-induced enterocolitisKhashayar Esfahani
BMJ Case Reports|October 31, 2014
An unusual cause of STEMI and cardiac tamponadeKhashayar Esfahani
Lung Cancer (Auckland, N.Z.)|February 18, 2017
HSP90 as a novel molecular target in non-small-cell lung cancerKhashayar Esfahani, Victor Cohen
Current Oncology (Toronto, Ont.)|April 26, 2024
A Review of Practice-Changing Therapies in Oncology in the Era of Personalized MedicineMariana Pilon Capella, Khashayar Esfahani
The New England Journal of Medicine|May 18, 2017
Reversal of Autoimmune Toxicity and Loss of Tumor Response by Interleukin-17 BlockadeKhashayar Esfahani, Wilson H Miller
The New England Journal of Medicine|June 11, 2020
Tofacitinib for Refractory Immune-Related Colitis from PD-1 TherapyKhashayar Esfahani, Marie Hudson, Gerald Batist
Journal of Oncology Practice|October 11, 2017
Programmed Cell Death Ligand 1-Induced Coma From Diffuse CerebritisPloa Desforges, Khashayar Esfahani, Nathaniel Bouganim
Journal of Cutaneous Medicine and Surgery|August 18, 2022
Survey of Oncologists and Dermatologists in Canada on the Management of Acneiform Eruptions Induced by Epidermal Growth Factor Receptor InhibitorsRachel Bierbrier, Khashayar Esfahani, Kevin Pehr
Frontiers in Oncology|August 8, 2014
A Systemic Review of Resistance Mechanisms and Ongoing Clinical Trials in ALK-Rearranged Non-Small Cell Lung CancerKhashayar Esfahani, Jason Scott Agulnik, Victor Cohen
Journal of Oncology Practice|July 14, 2018
Refractory Neutropenia Secondary to Dual Immune Checkpoint Inhibitors That Required Second-Line ImmunosuppressionNicholas Meti, Tina Petrogiannis-Haliotis, Khashayar Esfahani
Pageof 5

Showing results (1-10 of 47) with videos related to

Sort By:
Pageof 5
Journal for Immunotherapy of Cancer|December 23, 2018
Taking the bull by the horn: the frontline use of infliximab for the treatment of immune checkpoint inhibitor-induced enterocolitisKhashayar Esfahani
BMJ Case Reports|October 31, 2014
An unusual cause of STEMI and cardiac tamponadeKhashayar Esfahani
Lung Cancer (Auckland, N.Z.)|February 18, 2017
HSP90 as a novel molecular target in non-small-cell lung cancerKhashayar Esfahani, Victor Cohen
Current Oncology (Toronto, Ont.)|April 26, 2024
A Review of Practice-Changing Therapies in Oncology in the Era of Personalized MedicineMariana Pilon Capella, Khashayar Esfahani
The New England Journal of Medicine|May 18, 2017
Reversal of Autoimmune Toxicity and Loss of Tumor Response by Interleukin-17 BlockadeKhashayar Esfahani, Wilson H Miller
The New England Journal of Medicine|June 11, 2020
Tofacitinib for Refractory Immune-Related Colitis from PD-1 TherapyKhashayar Esfahani, Marie Hudson, Gerald Batist
Journal of Oncology Practice|October 11, 2017
Programmed Cell Death Ligand 1-Induced Coma From Diffuse CerebritisPloa Desforges, Khashayar Esfahani, Nathaniel Bouganim
Journal of Cutaneous Medicine and Surgery|August 18, 2022
Survey of Oncologists and Dermatologists in Canada on the Management of Acneiform Eruptions Induced by Epidermal Growth Factor Receptor InhibitorsRachel Bierbrier, Khashayar Esfahani, Kevin Pehr
Frontiers in Oncology|August 8, 2014
A Systemic Review of Resistance Mechanisms and Ongoing Clinical Trials in ALK-Rearranged Non-Small Cell Lung CancerKhashayar Esfahani, Jason Scott Agulnik, Victor Cohen
Journal of Oncology Practice|July 14, 2018
Refractory Neutropenia Secondary to Dual Immune Checkpoint Inhibitors That Required Second-Line ImmunosuppressionNicholas Meti, Tina Petrogiannis-Haliotis, Khashayar Esfahani
Pageof 5